Johnson & Johnson Net Cash Flow 2012-2026 | JNJ
Johnson & Johnson annual/quarterly net cash flow history and growth rate from 2012 to 2026. Net cash flow can be defined as the total change in cash for the company over the given period.
- Johnson & Johnson net cash flow for the quarter ending March 31, 2026 was $-4.396B, a 295.73% decline year-over-year.
- Johnson & Johnson net cash flow for the twelve months ending March 31, 2026 was $-1.429B, a 120.41% decline year-over-year.
- Johnson & Johnson annual net cash flow for 2025 was $-4.396B, a 295.73% decline from 2024.
- Johnson & Johnson annual net cash flow for 2024 was $2.246B, a 70.95% decline from 2023.
- Johnson & Johnson annual net cash flow for 2023 was $7.732B, a 2247.78% decline from 2022.
|
Johnson & Johnson Annual Net Cash Flow (Millions of US $) |
|
|---|---|
| 2025 | $-4,396 |
| 2024 | $2,246 |
| 2023 | $7,732 |
| 2022 | $-360 |
| 2021 | $502 |
| 2020 | $-3,320 |
| 2019 | $-802 |
| 2018 | $283 |
| 2017 | $-1,148 |
| 2016 | $5,240 |
| 2015 | $-791 |
| 2014 | $-6,404 |
| 2013 | $6,016 |
| 2012 | $-9,631 |
| 2011 | $5,187 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $574.358B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |